Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen B Heitner

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
Journal of Cardiac Failure|July 20, 2023
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Anjali T Owens, Ahmad Masri, Theodore P Abraham, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
Journal of Cardiac Failure|July 20, 2023
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Anjali T Owens, Ahmad Masri, Theodore P Abraham, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Pageof 11